Compare
Kewaunee Scientific Corp vs Mesa Laboratories Inc vs Transcat Inc vs Cytek Biosciences, Inc.
| Latest fiscal year | Kewaunee Scientific Corp KEQU | Mesa Laboratories Inc MLAB | Transcat Inc TRNS | Cytek Biosciences, Inc. CTKB |
|---|---|---|---|---|
| Year ended | 2026-04-30 | 2026-03-31 | 2026-03-28 | 2025-12-31 |
| Revenue | $282.00M | $249.13M | $331.88M | $201.49M |
| Revenue growth (YoY) | +17.3% | +3.4% | +19.2% | +0.5% |
| Gross margin | 28.5% | 63.5% | 32.6% | 51.8% |
| Operating margin | 5.9% | 7.4% | 4.0% | -20.0% |
| Net margin | 3.4% | 2.7% | 1.6% | -33.0% |
| Net income | $9.62M | $6.71M | $5.38M | -$66.54M |
| EPS (Diluted) | $3.22 | $1.21 | $0.57 | n/a |
| Operating cash flow | $18.63M | $42.83M | $34.85M | -$4.69M |
| Free cash flow | $14.70M | $39.58M | $19.55M | -$8.77M |
| Cash & equivalents | $9.95M | $26.93M | $4.94M | $90.85M |
| Total assets | $178.31M | $427.75M | $480.49M | $461.54M |
| Total liabilities | $101.50M | $241.50M | $179.87M | $119.80M |
| Shareholders' equity | $74.72M | $186.25M | $300.62M | $341.74M |
| Return on year-end equity | 12.9% | 3.6% | 1.8% | -19.5% |
| Shares outstanding | 2.87M | 5.52M | 9.33M | 128.55M |
Revenue, most recent five fiscal years
| Fiscal year | Kewaunee Scientific Corp | Mesa Laboratories Inc | Transcat Inc | Cytek Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $282.00M Ended 2026-04-30 | $249.13M Ended 2026-03-31 | $331.88M Ended 2026-03-28 | $201.49M Ended 2025-12-31 |
| 1 year earlier | $240.47M Ended 2025-04-30 | $240.98M Ended 2025-03-31 | $278.42M Ended 2025-03-29 | $200.45M Ended 2024-12-31 |
| 2 years earlier | $203.75M Ended 2024-04-30 | $216.19M Ended 2024-03-31 | $259.48M Ended 2024-03-30 | $193.01M Ended 2023-12-31 |
| 3 years earlier | $219.49M Ended 2023-04-30 | $219.08M Ended 2023-03-31 | $230.57M Ended 2023-03-25 | $164.04M Ended 2022-12-31 |
| 4 years earlier | $168.87M Ended 2022-04-30 | $184.34M Ended 2022-03-31 | $204.96M Ended 2022-03-26 | $127.95M Ended 2021-12-31 |